SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* POLEWACZYK JAMES F (Last) (First) (Middle) ONE IDEXX DRIVE (Street) WESTBROOK ME 04092 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol IDEXX LABORATORIES INC /DE [ IDXX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Corporate Vice President
	3. Date of Earliest Transaction (Month/Day/Year) 02/14/2011
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/14/2011		M		714	A	$0	2,627	D
Common Stock	02/14/2011		M		258	A	$0	2,885	D
Common Stock	02/14/2011		M		400	A	$0	3,285	D
Common Stock	02/14/2011		M		282	A	$0	3,567	D
Common Stock	02/14/2011		F		560	D	$77.59	3,007	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$77.59	02/14/2011		A		7,715		(1)	02/13/2018	Common Stock	7,715	$0	7,715	D
Incentive Stock Option (right to buy)	$77.59	02/14/2011		A		1,288		(2)	02/13/2018	Common Stock	1,288	$0	1,288	D
Restricted Stock Unit	(3)	02/14/2011		A		967		(3)	(3)	Common Stock	967	$0	6,174	D
Restricted Stock Unit	(4)	02/14/2011		M			714	(4)	(4)	Common Stock	714	$0	5,460	D
Restricted Stock Unit	(5)	02/14/2011		M			258	(5)	(5)	Common Stock	258	$0	5,202	D
Restricted Stock Unit	(6)	02/14/2011		M			400	(6)	(6)	Common Stock	400	$0	4,802	D
Restricted Stock Unit	(7)	02/14/2011		M			282	(7)	(7)	Common Stock	282	$0	4,520	D

Explanation of Responses:

1. Grant of options to buy shares of common stock becomes exercisable as to 1,801 shares on each of 02/14/2012, 02/14/2013 and 02/14/2014, 1,800 shares on 02/14/2015, and the remaining 512 shares on 02/14/2016.

2. Grant of options to buy shares of common stock that vest on the fifth anniversary date (02/14/2016) of the grant.

3. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2012) of the date of grant.

4. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2008) of the date of grant.

5. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2009) of the date of grant.

6. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2010) of the date of grant.

7. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2011) of the date of grant.

Remarks:

	John B. Rogers, Attorney-in-Fact for James F. Polewaczyk	02/16/2011
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.